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Abstract 
This is a prospective study to assess a complementary treatment for genital warts after laser vaporization. 62 patients were 
enrolled in two randomized groups: A1: laser vaporization alone. A2: laser vaporization, followed with Pidotimod plus vitamin C for 2 
½ months. The latter treatment shortened the time of warts remission and marginally decreased the rate of the warts’ recurrence: 
81% versus 67% (N.S.). Despite the non-significant difference, this complementary treatment seems to have some efficiency.  
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Introduction 
Background  
For many years, remarkable interest has been 
shown in the immune response changes associated with 
different pathologic conditions, including pre-cancer 
lesions. It is possible that an immunodepressive condition 
precedes and accompanies certain diseases, although 
the particular condition could be transitory and reversible. 
Recent knowledge on this topic suggests that several 
compounds can modify this immune response, although it 
is difficult to distinguish the effect due to other contributing 
factors. Pidotimod (Polymod) is a synthetic compound: 
dipeptide, which has been shown to act as a biological 
response modifier (BRM). Older and recent studies 
indicated that pidotimod, given as monotherapy or as 
combined treatment, has immunostimulatory effects [1], 
[2]. Actually, Pidotimod showed biological and 
immunological activity on both the adaptive and the innate 
immune responses [3]. Similarly, persistent HPV infection 
was found lower among women reporting intake 
increased values of vitamin C [4]. Taking into account that 
Pidotimod and vitamin C, estimated separately, are 
considered efficient in increasing immunological activity 
and lowering HPV persistence respectively, our intention 
was to assess their combined action.  
Although there is no doubt that HPV related 
lesions possess a remarkable potential for spontaneous 
regression, if left untreated [5], immunosuppression for 
any reason is an established risk factor for HPV infections 
and related pathological conditions [6]. If we take into 
consideration the above-mentioned data, a faster 
regression of condylomatous lesions could be 
hypothesized after an immunostimulatory treatment. 
Considering that HPV lesions recur frequently after 
treatment, a complementary treatment should be 
considered to reduce the percentage of recurrences. After 
cryotherapy, clearance rates at three months are 63% to 
92% [7]. After laser therapy, clearance rate approach is of 
100% over one year [8], although recurrence can be up to 
45 % [7]. 
 
Aim of the study 
This is a prospective study to assess if a 
complementary treatment with Pidotimod (Polimod) plus 
vitamin C after laser vaporization for genital warts 
decreases the rate of recurrence. 
Materials and methods 
Sixty-two patients (aged 17-32 years, mean age 
22.3) with genital and/or perianal-perineal warts were 
included in the study. Mean time from first sexual  Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010  
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intercourse and mean number of Pap smears until warts 
appearance was of 4.3 (years) and of 2.4 (smears) 
respectively. Baseline demographics of the above 
patients are seen in the results.  The patients were 
recruited from a total of 65 women. Recruitment period 
started in June 2008 and ended in January 2009. Taking 
into account that genital warts usually regress postpartum 
and that the use of Pidotimod in the first three months of 
pregnancy is not recommended, pregnancy was included 
in the exclusion criteria. Similarly, any previous treatments 
were included in the exclusion criteria. Three patients 
were excluded from the study because they reported at 
least one previous therapeutic procedure in the last month 
(Podophylotoxine: Wartec and/or laser vaporization).  
Patients were eligible if they had (1) perianal-
perineal warts (Figure 1) diagnosed for the first time and 
not as a recurrence; (2) did not receive any previous 
treatment. As this is a preliminary study, no power 
calculation of the appropriate sample size was conducted 
and “all available” patients were included in the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All patients were treated with laser vaporization using 
CO2 laser with “painting” motion technique (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Depending on the further treatment, patients 
were randomly subdivided in 2 groups (drawing letters A1 
or A2 from a box): A1 with 30 patients and A2 with 32 
patients. After the therapeutic procedure, patients 
belonging to the group A2 received an additional 
treatment with Pidotimod 800 mg (2 sachets/day) plus 
vitamin C (1000 mg/per day) for 15 days, and a further 
treatment with the same regimens in reduced doses for 
two more months (Pidotimod 1 sachet/day and vitamin C 
500 mg/per day). Clinical and colposcopic examination 
was repeated  at 10 weeks intervals and a final 
examination within 6 months was made for all the patients 
(a maximum of 3 examinations for each patient). 
Assessors were blinded to the patient’s treatment 
allocation.  
A regulatory approval and written consents were 
obtained from the Scientific Hospitals’ Committee and 
participants respectively. There was no funding for the 
trial.  
Results 
The mean number of sexual partners was 4.5 
(range 1-9), a history of oral contraception was recorded 
in 6 patients and heavy smoking (more than 20 cigarettes 
per day) was reported by 22 patients. 
Clinical and/or colposcopic disappearance of 
warts was diagnosed in 20 cases (67%) of group A1 and 
26 cases (81%) of group A2, without clinical recurrence 
within six months from initial evaluation: showing a trend 
of increased efficacy of pidotimod and vitamin C use. 
Clinical disappearance of warts was obvious in 18 cases 
of group A1 and 25 cases of group A2 with a minute 
colposcopic resistance of the remaining patients. No 
adverse effects were reported in group A2 patients, apart 
for one patient who reported nausea during the second 
day of treatment (probably unrelated to the drug, because 
during the same day two more members of her family had 
the same symptom). 
Although no statistical difference was found 
comparing groups A1 and A2 (p=0.2), which could be 
attributed to small numbers, a possible beneficial effect 
must not be excluded taking into account the obvious 
difference in percentages. In addition, shorter time of 
warts remission was concluded in group A2 patients as 
for four patients of group A2 and one patient of group A1, 
cure was confirmed in the second visit. Although it was 
not possible to determine the exact time of remission in 
the above cases, this ranged between 10 and 20 weeks 
(time between first and second visit).  
Discussion 
The cellular components of the immune system 
include the lymphocytes that are responsible for the 
production of antibodies. It seems that, in certain 
circumstances, a significant decrease in percentages of 
CD3 and CD4 populations can be observed and that 
pidotimod can positively impair these alterations [2]; in  Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010  
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addition, pidotimod stimulates the release of cytokines 
and drives T cell proliferation [9]. Similarly, certain 
pathologic conditions are associated with significant 
changes in immune response and pidotimod is able to 
positively affect these disturbances. Although, our study 
did not include lab evaluations, a possible similar 
mechanism could be proposed for the marginal beneficial 
results of pidotimod in our patients, taking into account 
that CD4 reductions precede or accompany pathologic 
conditions of the lower genital tract.  
The efficacy of pidotimod was previously shown 
in vulvar papillomatosis with a good safety profile [10]. 
Similarly, imiquimod (Aldara [5% cream]-Graceway 
Pharmaceuticals), an immune response modifier used for 
the topical treatment of anogenital warts, has an 
acceptable safety profile (with local inflammatory 
reactions as the most frequent adverse effects).   
However, complete clearance of warts showed in ≤ 50% 
of patients and recurrence rates exceeded 20% at 6 
months [11].  
Although, our results could be impaired from 
other co-factors (like a better “initial” immunologic status 
of group A2), a possible beneficial effect of pidotimod on 
HPV related lesions could not be excluded. Furthermore, 
the marginally younger age, fewer sexual partners and 
less heavy smoking of group A2 are not significantly 
different from those of group A1 and thus could not impair 
the final findings. Further studies with an increased 
number of patients could clarify the possible beneficial 
action of pidotimod in HPV condylomatosis lesions.   
Conclusion 
Treatment with Polimod and vitamin C, after 
laser vaporization of genital warts could be efficient in 
decreasing the rate of recurrences in HPV related 
conditions. If this beneficial effect was confirmed in further 
studies, it could be attributed to the fact that the combined 
action of polimod and vitamin C, probably increases 
immunity and natural defense and decreases persistence 
of HPV infection. Further studies with more cases should 
be encouraged, in order to assess complementary 
systemic treatments after laser therapy or cryotherapy in 
genital warts, due to the high rate of recurrences. 
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